12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Mepolizumab: Phase III started

GlaxoSmithKline began the 24-week, double-blind, placebo-controlled, international Phase III MEA115575 trial to evaluate 100 mg subcutaneous mepolizumab every 4 weeks for up to 20 weeks plus an oral corticosteroid in...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >